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Objectives We attempted to correlate echocardiographic analysis of diastolic function with changes of myocardial collagen
in middle-aged patients with heart failure (HF) despite normal ejection fraction (EF).
Background Increased collagen deposition may contribute to the deterioration of the left ventricular compliance and diastolic
dysfunction in HF.
Methods We investigated 41 patients (median age 50 years [interquartile range: 41 to 57 years]) with normal EF (median
62% [interquartile range: 56% to 70%]) whose endomyocardial biopsies were taken previously. Assessment of
diastolic function was performed by mitral-flow and tissue Doppler measurements. Sirius red and immunohisto-
logic staining was performed to determine collagen volume fraction (CVF) and cross-linking, collagen types I and
III expression, and lysyl-oxidase (LOX) expression. Expression of collagen messenger ribonucleic acid was deter-
mined by real-time polymerase chain reaction.
Results Twenty-six patients with HFNEF with diastolic dysfunction showed a significant increase in total collagen and col-
lagen I expression compared with that of 15 controls. This was accompanied with enhanced collagen cross-
linking and LOX overexpression in HFNEF. Among all flow Doppler, only deceleration time of E was associated
with CVF (R  0.43), whereas tissue Doppler parameters correlated with CVF, collagen I at the protein and
mRNA levels (E’ [R  0.58, 0.60, 0.45]; E’/A’ [R  0.32, 0.36, 0.31]), and left ventricular filling in-
dex (E/E’ [R  0.72, 0.68, 0.63]), respectively. No correlation with collagen III was found. The degree of collagen
cross-linking and LOX expression was related to E’ (R  0.55 and 0.60) and E/E’ (R  0.72 and 0.71), re-
spectively, but not to flow Doppler. Collagen overexpression correlated with reduced exercise capacity.
Conclusions Patients with HFNEF showed increased content of myocardial collagen type I, enhanced collagen cross-linking, and
LOX expression, which were associated with impaired diastolic tissue Doppler parameters. (J Am Coll Cardiol
2011;57:977–85) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.024Differential diagnosis of exertional dyspnea and reduced
exercise capacity provide a challenge in the clinical routine.
Particularly, patients with mild symptoms are misdiagnosed,
an event followed by either inadequate treatment or no
treatment at all. Their symptomatology could be of noncar-
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2010, accepted October 18, 2010.diac (1–3) or cardiac (4–6) origin. One-half of the patients
presented with a preserved left ventricular (LV) ejection
fraction (EF) (7). This clinical syndrome, called heart failure
with normal ejection fraction (HFNEF), is found predom-
inantly in the elderly, especially with hypertension and
hypertensive heart disease (HHD). However, underlying
pathophysiologic mechanisms in HFNEF are only partially
understood. Predominantly diastolic dysfunction (7–11)
with impaired LV compliance and diastolic filling (12–16)
are thought to be responsible for the symptoms. In clinical
practice, echocardiography is the first-line diagnostic
method (17,18). However, patients with a lower grade of
comorbidity and/or an early stage of disease are difficult to
diagnose (19). Because mitral-flow Doppler revealed lower
accuracy (13,20), tissue Doppler (TDI) is suggested as the
ultimate diagnostic approach (17). Nevertheless, because of
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prognostic role is still under
investigation.
In post-mortem studies in pa-
tients with HHD (22,23), an en-
hanced accumulation of collagen I
and III fibers within the myocar-
dial interstitium and perivascular
extracellular matrix was found
(24). In hypertensive animal
models with LV hypertrophy and
preserved systolic function, in-
creased amounts of collagen were
accompanied by abnormal dia-
stolic stiffness (25,26) but not
ultimately in hypertrophied myo-
cardium without fibrosis (27,28).
Because increased myocardial fi-
brosis may contribute to the de-
terioration of the LV compliance
and diastolic dysfunction in heart
failure (29,30), we investigated
the reliability of echocardiography
to recognize the changes in
amounts and quality of myocardial
collagen as a sign of early cardiac remodeling in HFNEF.
Therefore, we included middle-aged patients who were symp-
tomatic under exercise conditions, thus aiming to find an
optimal noninvasive diagnostic approach for early diagnosis
and prevention of disease progression.
Methods
Study population. Patients presenting with heart failure
HF) symptoms and reduced exercise capacity despite pre-
erved LVEF (50%) who showed diastolic dysfunction
ccording to echocardiographic analysis and European So-
iety of Cardiology recommendations (17) were enrolled in
he study. All patients had at least 1 HF-related hospital-
zation and were screened for noncardiac causes of symp-
oms, including lung function tests. Ventilatory system–
elated exertional dyspnea was excluded by performing
piroergometry. Exercise capacity and exertional dyspnea
ere evaluated by a 6-min walk test, bicycle ergometry, and
-terminal pro–brain natriuretic peptide (NT-proBNP)
lasma levels (31,32). Patients with significant coronary
rtery diseases verified by angiography; atrial fibrillation;
nd significant heart valve, lung, or renal diseases were
xcluded. Patients without symptoms and signs of conges-
ive heart failure but with atypical angina or intermittent
rrhythmias who underwent right ventricular (RV) biopsy
or evaluation of cardiomyopathy (33) and showed regular
ystolic and diastolic LV function were enrolled as controls.
ndomyocardial biopsies (EMBs) were obtained following
nternational recommendations (33). All patients investi-
Abbreviations
and Acronyms
CVF  collagen volume
fraction
E/A  ratio of early peak
(E) to late peak (A) mitral-
flow velocities
E’/A’  early (E’) to late
(A’) diastolic velocity ratio
of mitral annulus
E/E’  left ventricular
filling index
HFNEF  heart failure with
normal ejection fraction
HHD  hypertensive heart
disease
LAVI  left atrial volume
index
LOX  lysyl-oxidase
LV  left ventricular
LVMI  left ventricular
mass index
TDI  tissue Doppler
imagingated provided their written informed consent for invasive ldiagnostic procedures. The research protocol was approved
by the local institutional review committee (approval
225-07).
Echocardiography and Doppler measurements. Tran-
sthoracic echocardiography was performed using a GE
Vingmed ultrasound system 5 or VIVID 7 (2.5 MHz)
(Horten, Norway) by an independent investigator blinded
for invasive data analysis. Cardiac cycles were stored in a
cineloop format. Chamber dimensions were determined by
standard procedures, including left ventricular mass index
(LVMI) and left atrial volume index (LAVI). End-diastolic
wall stress was calculated as previously described (34).
Mitral and pulmonary venous flow Doppler and TDI were
recorded in the apical 4-chamber view according to guide-
lines (17). Mitral in-flow measurements included peak early
(E) and late (A) flow velocities, the E/A ratio, deceleration
time of E (DT), and isovolumic relaxation time (IVRT).
Pulmonary venous flow measurements included peak S, D,
and atrial reversal velocities. The S’ and early (E’) and late
(A’) diastolic peak velocities were assessed at septal and
lateral mitral origin and expressed as mean. The mean
values of the E’/A’ ratio and LV filling index (E/E’) were
determined.
EMBs. EMBs were obtained from the RV septum using a
flexible bioptome (Westmed, St. Ingbert, Germany) via the
femoral vein approach. Endomyocardial biopsies were di-
rectly embedded in optimal cutting temperature compound
(Miles Laboratories, Inc., Elkhart, Indiana) and frozen at
70°C. With a cryostat, the biopsies were cut into 4-mm
thin sections, mounted on a slide, and fixed in acetone for
10 min. The tissue pieces were frozen in liquid nitrogen and
stored at 70°C for subsequent histologic analysis (35).
Histology and immunohistology. Formalin-fixed tissue
was processed for paraffin embedding, sectioned in standard
thickness, and stained with collagen-specific Picrosirius red
(F3BA in aqueous picric acid) (6). The fraction of myocar-
dial volume occupied by fibrillar collagen (collagen volume
fraction [CVF]) was determined by quantitative morphom-
etry with an automated image analysis system (AnalySYS,
Soft Imaging System GmbH, Hammer, Germany) (6). To
istinguish between cross-linked (insoluble) and non–cross-
inked (soluble) collagen, a colorimetric procedure was used
36). First, a fast green/Sirius red assay was performed to
dentify and quantify total collagen. In a second step, a
ircol-based assay was performed to obtain and quantify
oluble collagen. The amount of insoluble collagen was
alculated by subtracting the amount of soluble collagen
rom the amount of total collagen. The degree of cross-
inking was calculated as the ratio between the insoluble and
oluble forms of collagen. Cross-linking was determined
etrospectively in only 23 patients (14 with HFNEF and 9
ontrols) for whom EMB samples were available. To
etermine expression of collagen I and III, immunohisto-ogic staining was performed using standard techniques with
Ni
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stained collagen. The exact procedure is described in the
Online Appendix. The expression of lysyl-oxidase (LOX),
the enzyme responsible for collagen cross-linking, was
determined retrospectively in 15 patients for whom EMB
samples were available (10 with HFNEF and 5 controls).
The results are expressed as semiquantitative values (absent,
mild, moderate, and intense expression). The detailed pro-
cedure is available in the Online Appendix.
The histomorphologic study was performed by a pathol-
ogist blinded to patient data. To determine myocyte dimen-
sions, the maximal myocyte diameter was measured through
the nucleus for 10 cells per sample. Using a standard
equation for sample size, 10 measurements reduced the
sampling error to 3%.
RNA isolation, reverse transcription, pre-amplification,
and real-time polymerase chain reaction. Total RNA
was extracted from the EMB by the Trizol method.
Additional purification was performed using the
ChargeSwitch total RNA cell kit (Invitrogen GmbH,
Karlsruhe, Germany). TaqMan gene expression assays
(Applied Biosystems Deutschland GmbH, Darmstadt,
Germany) were used for preamplification and real-time
polymerase chain reaction. The exact procedure is de-
scribed in the Online Appendix.
Statistical analysis. SPSS (version 13.0, SPSS Inc., Chicago,
Illinois) was used for statistical analyses. Continuous variables
are expressed as median with interquartile range. Two-sample
comparisons were performed using an unpaired t test for
normally distributed variables, Mann-Whitney U test for
non-normally distributed variables, and the Fisher exact or
Chi-square test for categoric data. The whiskers in the box
plots are defined as highest/lowest values under the outlier
cutoff (1.5 interquartile range). The Pearson coefficients for
linear and Spearman coefficients for nonlinear correlations
Patient CharacteristicsTable 1 Patient Characteristics
Demographics
Controls
(n  15)
HFNEF
(n  26) p Value
Women/men 4/11 15/11 0.502
Age (yrs) 50 (34–54) 51 (45–58) 0.108
NYHA functional class II/III 0/0 19/7 —
6-min walk test (m) 523 (479–573) 331 (285–383) 0.001
NT-proBNP (pg/ml) 47 (17–87) 186 (67–306) 0.007
BMI (kg/m2) 23.9 (21.6–28.7) 26.9 (23.3–31.7) 0.234
Concomitant disease
Arterial hypertension 1 19 0.002
Diabetes mellitus 0 4 —
Obesity 2 8 0.193
Hyperlipoproteinemia 4 13 0.211
Smoker 4 6 0.948
Data are expressed as n or median (25% to 75% percentiles).
BMI  body mass index; HFNEF  heart failure with normal ejection fraction; NT-proBNP 
-terminal pro–brain natriuretic peptide; NYHA  New York Heart Association.were used. Regression analyses and curve fitting were per-formed to determine exact relations. A value of p  0.05 was
considered to be statistically significant in all analyses.
Results
Patient characteristics. Patient characteristics are summa-
rized in Table 1. The study population was relatively young
(median age 50 years) and included 26 patients with
HFNEF and 15 controls. Patients with HFNEF showed a
significantly higher prevalence of hypertension, diabetes,
and obesity. They had higher New York Heart Association
functional class and NT-proBNP levels and lower 6-min
walk test and bicycle exercise-test levels than the controls.
There was no difference between groups in age, sex, and
body mass index.
Echocardiography. Heart dimensions and flow and tissue
Doppler measurements are listed in Table 2. In patients
with HFNEF and controls, LV was not dilated. Patients
with HFNEF showed a trend toward increased LVMI and
had increased wall stress and LAVI. They had normal
systolic function but showed borderline flow Doppler and
significantly impaired TDI diastolic parameters: decreased
E’ and E’/A and increased E/E’.
Echocardiographic Parametersin HFNEF Ve sus ControlsTable 2 Echo ardiographic Parametersin HFNEF Versus Controls
Heart Dimension
Controls
(n  15)
HFNEF
(n  26) p Value
LA parasternal (mm) 35 (32–38) 37 (33–42) 0.449
LAVI (ml/m2) 15.8 (12.7–19.2) 25.7 (17.5–29.0) 0.027
LVEDD (mm) 50 (48–52) 51 (46–54) 0.575
Septum (mm) 11 (10–11) 12 (10–13) 0.198
Posterior wall (mm) 10 (9–11) 11 (9–12) 0.352
LVMI (g/m2) 93 (89–112) 120 (93–143) 0.076
LVEDVI (ml/m2) 95 (91–101) 79 (63–100) 0.166
LVEF (%) 66 (59–72) 67 (58–74) 0.475
EDWS (kdyne/cm2) 17.4 (14.5–26.3) 30.9 (23.8–38.5) 0.017
Mitral flow
E (m/s) 0.77 (0.60–0.96) 0.90 (0.7–1.06) 0.067
A (m/s) 0.76 (0.60–0.92) 0.84 (0.70–1.00) 0.004
E/A 1.28 (1.00–1.50) 1.12 (0.87–1.26) 0.108
DT (ms) 202 (179–216) 225 (197–251) 0.113
IVRT (ms) 92 (80–103) 97 (93–108) 0.153
Pulmonary vein flow
Systolic (m/s) 0.56 (0.48–0.74) 0.60 (0.55–0.69) 0.712
Diastolilc (m/s) 0.70 (0.56–0.75) 0.58 (0.46–0.72) 0.462
Ar (m/s) 0.31 (0.30–0.35) 0.35 (0.31–0.41) 0.319
S/D 0.93 (0.67–1.11) 1.24 (0.92–1.29) 0.149
Tissue Doppler
S’mean (m/s) 0.10 (0.07–0.12) 0.09 (0.08–0.10) 0.624
E’mean (m/s) 0.12 (0.09–0.15) 0.06 (0.05–0.07) 0.001
A’mean (m/s) 0.09 (0.06–0.10) 0.08 (0.05–0.10) 0.898
E’/A’mean 1.55 (1.12–2.15) 0.87 (0.61–1.01) 0.001
E/E’mean 7.2 (5.3–8.1) 16.0 (11.5–18.7) 0.001
Data are expressed as median (25% to 75% percentiles).
Ar  atrial reversal; DT  deceleration time of E; EDWS  end-diastolic wall stress; IVRT 
sovolumic relaxation time; LA left atrial; LAVI left atrial volume index; LVEDDleft ventricular
end-diastolic diameter; LVEDVI left ventricular end-diastolic volume index; LVEF left ventricular
ejection fraction; LVMI  left ventricular mass index; other abbreviations as in Table 1.
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in patients with HFNEF. Figure 1 illustrates representative
istologic staining from EMBs in patients with HFNEF
howing increased Sirius red collagen content and collagen I
nd LOX expression compared with controls. A larger pro-
ortion of collagen I–stained area fraction was detected in
atients with HFNEF compared with controls (median 11.5%
interquartile range (IQR): 6.7% to 14.7%] vs. 2.7% [IQR:
.8% to 4.2%]; p  0.005), but expression of collagen III did
ot differ (Fig. 2), which resulted in an increased collagen I/III
atio (1.11 [IQR: 0.72 to 1.52] vs. 0.58 [IQR: 0.20 to 0.96];
 0.020). The Picrosirius red staining showed higher
alues of CVF in patients with HFNEF (13.1% [IQR:
0.08% to 18.40%] vs. 4.1% [IQR: 3.25% to 7.04%]; p 
.001) (Fig. 2E) that are also within the expected range for
atients with chronic fibrosing cardiac diseases. Myocyte
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Figure 1 Representative Histologic Staining From Endomyocard
Patients with heart failure with normal ejection fraction (HFNEF) show an increased
and increased expression of collagen type I and lysyl-oxidase compared with contriameters were not significantly increased in comparisonith those of the controls (20.0 m [IQR: 17.0 to 23.0 m]
s. 18.0 m [IQR: 17.0 to 20.2 m]; p  0.258).
Collagen cross-linking and expression of myocardial
LOX in patients with HFNEF. The degree of collagen
cross-linking was significantly increased in the myocardium
of patients with HFNEF compared with controls. The
amount of insoluble collagen was higher and amount of
soluble collagen was lower in patients with HFNEF than in
controls (Table 3). Insoluble collagen and cross-linking
correlated strongly with CVF (r  0.802; p  0.002 and r 
.880; p  0.001, respectively). Considering LOX expres-
sion as a semiquantitative variable and taking into account
the distribution within groups (3 intense, 6 moderate, and 1
mild in patients with HFNEF vs. 1 absent and 4 mild in
controls), a Mann-Whitney U test showed significant dif-
ference (Mann-Whitney U  2.000; p  0.003). A regres-
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.63; p  0.012), and amount of insoluble collagen (r 
.68; p  0.005).
xpression level of mRNA for collagen I and III in
atients with HFNEF. The results of increased collagen I
xpression in patients with HFNEF with diastolic dysfunc-
ion were confirmed on the mRNA level. The expression of
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Figure 2 Total Collagen Amount and Collagen Quality
in Patients With HFNEF Versus Controls
Expression of collagen type I is increased in patients with heart failure with
normal ejection fraction (HFNEF) at both (A) mRNA and (B) protein levels,
whereas there is no difference in collagen type III expression at (C) mRNA and
(D) protein levels, compared with controls. Patients with HFNEF reveal
increased collagen volume fraction (CVF) as shown by (E) Sirius red staining
and (F) collagen cross-linking.ollagen I mRNA was 2.1-fold increased in patients withFNEF (p  0.001), and a trend was shown toward
ncreased expression of collagen III mRNA by 1.6-fold
Fig. 2).
iastolic parameters versus myocardial collagen content
n HFNEF. Approximated wall stress showed moderate
orrelations with CVF and collagen I expression (r 0.40; p
.031 and r  0.45; p  0.021, respectively), whereas
VMI and LAVI did not. Flow Doppler showed that DT
nd A correlated weakly with CVF (r  0.43; p  0.017
nd r  0.52; p  0.031, respectively), but E, E/A, and
VRT were not related either to total collagen or collagen I
r III expression at the protein or mRNA level. Pulmonary
enous flow was available in 42% of patients; S/D ratio
orrelated with collagen I expression, and S, D, and atrial
eversal did not show any correlation. The TDI data showed
ignificant correlations with CVF and collagen I expression
ut not collagen III expression; E’ showed an inverse
orrelation with CVF (r  0.60; p  0.001) and collagen
expression at the mRNA (r0.58; p 0.045) and protein
evels (r0.36; p 0.030) (Fig. 3). A’ was not associated
ith myocardial collagen. E’/A’ correlated with CVF (r 
0.32; p  0.048) and collagen I expression at the protein
r  0.36; p  0.026) and mRNA levels (r  0.31; p 
.035). The correlation with collagen III expression was not
ignificant (r  0.18; p  0.267 and r  0.20; p 
0.356, respectively). E/E’ was related significantly to CVF (r 
0.72; p  0.001) and collagen I expression at the protein (r 
0.68; p  0.001) (Fig. 3) and mRNA levels (r  0.63; p 
0.001). E/E’ was weakly related to collagen III expression at
the protein (r  0.33; p  0.029) and mRNA levels (r 
0.44; p  0.030). There were no associations between
myocyte diameter and diastolic TDI parameters.
Diastolic parameters versus collagen cross-linking and
LOX expression. From flow Doppler, only DT correlated
with collagen cross-linking, whereas TDI parameters E’,
E’/A’, and E/E’ showed significant correlations with soluble
and insoluble collagen and cross-linking (Table 4). The
LOX expression was associated with TDI but not with
conventional flow Doppler parameters. Elevated E/E’ pro-
vided the best correlation, with an increasing degree of
collagen cross-linking, suggesting an impaired LV compli-
ance in patients with HFNEF with myocardial collagen
overexpression.
Collagen Cross-Linking inPatients With HFNEF Versus ControlsTable 3 Collage Cro s-Linking inPatients With HFNEF Versus Controls
Controls
(n  9)
HFNEF
(n  14) p Value
Soluble collagen (g/mg) 0.58 (0.52–0.68) 0.41 (0.35–0.52) 0.005
Insoluble collagen (g/mg) 0.45 (0.41–0.59) 0.66 (0.57–0.73) 0.008
Cross-linking (%) 0.77 (0.63–1.01) 1.69 (1.04–2.09) 0.002
Variables are expressed as median (25% to 75% percentiles), values of collagen are expressed as
g of collagen/mg of total protein).
Abbreviation as in Table 1.
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The key finding of our study was evidence of a relationship
between structural changes of the extracellular matrix and
echocardiographic TDI in middle-aged patients already
exhibiting HFNEF largely owing to HHD. Increased
myocardial collagen content and cross-linking in EMBs
indicated an early remodeling process that is able to increase
ventricular stiffness, compromising LV filling. Opposite to
conventional flow Doppler, TDI of diastolic function and
LV filling index as a noninvasive measure of impaired LV
compliance revealed significant correlations with myocardial
collagen content and collagen cross-linking, which con-
firmed their superior diagnostic accuracy in patients with
HFNEF showing mild diastolic dysfunction.
The pathophysiology of HFNEF is poorly understood,
and the correct diagnosis in everyday clinical settings still
remains a challenge. Mitral-flow Doppler is no longer
recommended as the method of choice because of its low
accuracy (17,18). Tissue Doppler provides the most reliable
diagnostic approach; however, its key parameter, LV filling
index (E/E’), also reveals disadvantages relating to unclear
cut-off values and its prognostic role in HFNEF. To further
evaluate the role of different echocardiographic techniques
in HFNEF, we correlated their diastolic parameters with
changes of the collagen amount/quality in EMBs, known to
be critical for LV compliance. Besides increased myocyte
tension (37) and endothelial dysfunction (35,38), there are
changes in the extracellular matrix, and particularly those in
collagen composition that influence the passive mechanical
properties of the myocardium (27,30,39). Because myocar-
dial fibrosis is uniform for all sites in the heart in HHD, the
changes in extracellular matrix and collagen accumulation
can be observed by biopsy of the RV interventricular septum
as performed in our study. We were able to find an increased
total amount of cardiac collagen in patients with HFNEF,
which is in agreement with findings from patients with
HHD (22,23), including preclinical data (25,40,41).
However, the measurement of collagen content is a less
accurate expression of fibrosis in hypertrophied hearts be-
cause it is influenced by increments of ventricular mass.
Formation and distribution of new collagen fibers, as
Correlation of Diastolic Indexes From Mitral-FlowInsoluble Collagen, Collagen Cross-Linking, andTable 4 Correlati n of Diastolic I dexes roInsoluble Collagen, Collagen Cross-
CVF
(n  41)
Insoluble
(n 
E 0.03 (0.431) 0.22
E/A 0.25 (0.130) 0.04
IVRT 0.12 (0.528) 0.21
DT 0.43 (0.017) 0.51
E’mean 0.58 (0.001) 0.47
E’/A’mean 0.32 (0.048) 0.30
E/E’mean 0.72 (0.001) 0.55
Data are expressed as Pearson correlation coefficient (p value).
CVF  collagen volume fraction; LOX  lysyl-oxidase; other abbrevicharacterized by collagen cross-linking or collagen I/IIIratio, contribute to the functional consequence of myocar-
dial fibrosis and therefore are found to be related to
myocardial diastolic stiffness (24,41). Therefore, LV cham-
ber stiffness will be affected by the amount and quality of
cardiac collagen, as previously shown (6,23,30,36,42,43),
indicating that changes in plasma levels of matrix metallo-
proteinase/tissue inhibitor of metalloproteinase and collagen
propeptides reflect an increase in systemic collagen turnover.
The association between TDI and myocardial fibrosis in our
study was independent from the LV hypertrophy parameter
obtained by LVMI, indicating the importance of fibrosis for the
compliance properties of the LV (27), which support the findings
from animal models (25,26,28). Data from patients with hyper-
tension have led to the suggestion that the myocyte cross-sectional
area is almost double its normal value but does not change with
progression to cardiac failure, when cell lengthening is the pre-
dominant cellular change (44). Similarly, we found no significant
changes in myocyte diameters in our HFNEF population with a
short history of disease and borderline increased LVMI. However,
there exists variability in muscle fiber diameter because fibers
surrounded by collagen may become atrophic, whereas those at a
distance may be hypertrophied (Fig. 1). Therefore, although the
association of TDI and myocardial collagen appears not to be
influenced by hypertrophy and myocyte shape changes, the vari-
ability of fiber diameters calls for caution in interpretation of these
results.
Correlation of mitral-flow Doppler with myocardial collagen
in patients with HFNEF. Among measured-flow Doppler
parameters, only DT was associated with myocardial colla-
gen content. This result is in line with findings showing that
DT reflects LV chamber stiffness (45). We did not find any
significant relationship with early in-flow velocity or IVRT.
They represent mainly early diastolic changes reflecting an
active process of diastolic LV relaxation, which also might
explain its unmodifiable correlation with cardiac fibrosis.
Pulmonary vein flow Doppler was also not found to be
sensitive enough to detect early changes of cardiac remod-
eling in patients with mild HFNEF. In contrast to other
studies involving diastolic HF (11,15,16,19), our population
was younger and showed only a mild increase in LVMI and
borderline LA volume, without any apparent severe con-
Tissue Doppler With CVF,Expressiontral-Flow and Tissue Doppler With CVF,
g, and LOX Expression
en Cross-Linking
(n  23)
LOX
(n  15)
) 0.33 (0.139) 0.11 (0.705)
) 0.02 (0.938) 0.40 (0.135)
) 0.21 (0.449) 0.09 (0.790)
) 0.41 (0.135) 0.14 (0.687)
) 0.55 (0.010) 0.60 (0.018)
) 0.28 (0.230) 0.35 (0.198)
) 0.72 (0.001) 0.71 (0.003)
s in Table 2.andLOXm Mi
Linkin
Collag
23)
(0.336
(0.867
(0.448
(0.050
(0.031
(0.186
(0.007comitant diseases such as severe hypertension, coronary
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thy which per se can influence mitral-flow properties.
In conclusion, flow Doppler measurements correlate with
hemodynamic changes in patients with HFNEF only indi-
rectly and therefore cannot provide unequivocally any of the
changes in intrinsic LV characteristics, at least during an
early form of the disease. According to our findings, this
becomes clinically relevant especially in patients with only
mild disturbances, relatively low filling pressure, and an
early stage of remodeling when transmitral flow alone
cannot serve as a reliable diagnostic method.
Correlation of TDI with myocardial collagen content in
patients with HFNEF. Because it is believed that intrinsic
changes of LV tissue precede the impairment of transmitral
flow, TDI might already recognize early changes in the
tensile characteristics of LV, not yet manifested as being
part of a mitral-flow pattern. In support of this belief, we
showed a significant association of TDI parameters with not
only the extent of myocardial collagen accumulation but also
with the quality alteration of collagen, as characterized by
the degree of cross-linking and expression of the crucial
regulatory enzyme LOX, even in a mild form of diastolic
dysfunction. Early diastolic mitral movement E’, which is
also partially related to the compliance disturbance of the
LV (13), correlated with CVF and cross-linking. Opposite
of this correlation, atrial contraction movement A’ was not
related to myocardial collagen content. In our patients with
borderline LAVI changes, A’ seemed not to be affected.
The strongest association was found between LV filling
index E/E’ and the degree of myocardial collagen amount,
collagen cross-linking, and expression of LOX. These findings
confirm the hypothesis that cardiac fibrosis and the remodeling
process are associated with the passive LV compliance charac-
teristics (13,30). This relationship was supported in partic-
lar by a connection to collagen I expression, which is
nown to possess extreme tensile properties. Consequently,
ur patients with HFNEF with elevated E/E’ suffered from
xercise intolerance, as obtained by the 6-min walk test.
his indicates that LV compliance disturbances—associated
s well with cardiac fibrosis—can indeed contribute to the
ower cardiac performance despite normal contractile LV
unction as confirmed by rest echocardiography.
onclusions
atients with HFNEF showed increased myocardial colla-
en content, particularly collagen type I, but also enhanced
ollagen cross-linking and LOX expression, which were
ssociated with impaired diastolic function and reduced
xercise tolerance. This association suggested that quantity
nd quality of myocardial collagen influence the compliance
haracteristics and performance of the LV in HFNEF.
orrelation of diastolic TDI parameters with increased
ardiac collagen expression and cross-linking implicates that
DI reflects the hemodynamic properties of the LV already
resent among mild forms of HFNEF. Therefore, inmiddle-aged patients with symptoms manifested solely
during exercise conditions, TDI should substantiate a
method of choice for the evaluation of diastolic function.
Additionally, our findings suggest that therapeutic strategies
directed not just at reducing the amount of collagen but also
at reducing collagen cross-linking should be implemented in
the prevention of the adverse impact of myocardial fibrosis
on cardiac function in patients with HFNEF. In this regard,
it was reported that treatment with the loop diuretic
torasemide was associated with correction of LOX overex-
pression, enhanced collagen cross-linking, and normaliza-
tion of LV chamber stiffness in patients with HF (36).
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